Registration Instructions: You will need your state society account to register for any live or on-demand webinar, which will enable you to register for future events and webinars with just one click. Once you click the "Register" button on this page, you will be redirected to the eLearning portal, where you will follow the below steps to complete your registration.
If you DO NOT have an account:
Click the green "Register" button on the screen, and you will be directed to "Your Cart." Click the "Log In" button near the top of the page.
Then click “eLearning” at the top of your profile page to go back to the eLearning portal. In the box on the left side of the screen, click on the “Cart” link. The green box in the upper right corner will then say “You are registered.”
If you have an account:
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access the on-demand event. For assistance with registration or if you do not receive an email, please contact us.
PRO TIP: If you save your password to your computer and remain logged in, you can register for additional events and webinars in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the event.
Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence, and performance gaps exist in the optimal management of metastatic castration-sensitive prostate cancer (mCSPC).
This webinar addresses some of the challenges in optimal sequencing of care in mCSPC and strategies for translating new research into patient care strategies.
Pedro C. Barata, MD, MSC
Assistant Professor, Deming Department of Medicine Division of Hematology/Oncology, Genitourinary Cancers
Lisa M. Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor, UConn School of Pharmacy
Associate Professor, UConn School of Medicine
RECORDING COMING SOON
This activity was in collaboration with the Association of Community Cancer Centers (ACCC).
Novel immunotherapy drugs are used to treat advanced bladder cancer when chemotherapy is no longer working. However, only one in five patients responds to immunotherapy, likely due to biological differences in bladder cancer. Hear Dr. Andreev-Drakhlin—recipient of The ASCO Foundation 2020 Conquer Cancer Young Investigator Award— presents his research plans in using fibroblast growth factor receptor (FGFR) inhibitors for improving the effectiveness of immunotherapy for bladder cancer.
Alexander Andreev-Drakhlin, MD
Medical Oncology Fellow
University of Texas MD Anderson Cancer Center
VIEW ON-DEMAND RECORDING